Search Results
FAQs: Proposed federal spending cuts and blood cancer research and care
The Leukemia & Lymphoma Society (LLS) has heard great concerns from patients, caregivers, volunteers, healthcare professionals, researchers, community organizations and others who are fearful and confused by NIH spending cuts and other policies being proposed and implemented in Washington.
Harnessing METTL3 inhibition in acute megakaryoblastic leukemia driven by the t(1;22) fusion involving a member of the m6A writer complex
I want to understand how the t(1;22) translocation that involves a member of the m6A writer complex drives acute megakaryoblastic leukemia (AMKL). To identify culprit genes and pathways I will use multi-omics, including RNA, eCLIP, and TimeLapse Seq and proteomics. I will dissect the RBM15-MKL specific effects of a novel METTL3 inhibitor in primary murine and human AMKL in vitro and in vivo. My ultimate goal is to cure this rare infant leukemia by harnessing METTL3 inhibition.Helping Blood Cancer Patients and Caregivers Navigate the Financial Impact of COVID-19
The coronavirus (COVID-19) pandemic has been a challenging time for us all. It is especially so for cancer patients and survivors, who are at greater risk of getting sicker if they become infected with the virus because they might be immunocompromised.
Healing Happens Around The Dinner Table
Too many parents lose their children to blood cancer each year. It’s a devastating experience for families blindsided by the harsh realities of cancer treatment that wasn’t developed with their little ones in mind. These lives lost too soon are the reason parents of children touched by blood cancer advocate fervently for change. And it’s a cause their communities and loved ones are more than happy to join—developing better treatment options that are safer and more effective for children, causing fewer side effects and leading to better outcomes.
Helping Survivors Lead Longer Better Lives
Late last year I had the privilege of attending a special screening of the documentary American Symphony. The film chronicles the experiences of writer Suleika Jaouad and her husband musician Jon Batiste after learning that her acute myeloid leukemia (AML) had returned after years of remission. The movie shows how the couple navigates uncertainty, treatment, and their new normal afterwards.
Chlorambucil
Chlorambucil is FDA approved to treat people who have chronic lymphocytic leukemia (CLL), some types of non-Hodgkin lymphoma and advanced Hodgkin lymphoma.
Idarubicin
Idarubicin is FDA approved in combination with other antileukemic drugs to treat people who have acute myeloid leukemia in adults.
Ifosfamide
Ifosfamide is an FDA-approved cancer therapy that is used to treat several types of cancer including acute lymphoblastic leukemia and non-Hodgkin lymphoma. It may cause temporary loss of hair in some people. After treatment has ended, normal hair growth should return.
Teniposide
Teniposide is FDA approved along with other medicines as induction therapy to treat people who have refractory childhood acute lymphoblastic leukemia, non-Hodgkin lymphoma and other types of cancer. This medicine often causes a temporary loss of hair. After treatment with teniposide has ended, normal hair growth should return.
Olutasidenib
Olutasidenib is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
Targeting Oncoembryonic Antigens ROR1 and ROR2 For Therapy Of Patients With Hairy Cell Leukemia
We will study the function of ROR1 and ROR2 on HCL cells that we have collected from 120 patients, examining whether they influence expression of genes that can promote the growth/survival of HCL cells. We have made antibodies that are highly specific for ROR1 or ROR2 that react with HCL cells, but not normal blood cells or tissues. We will determine if these antibodies can be used as naked antibodies, antibody-drug conjugates, or in chimeric receptors on T cells to specifically kill HCL cells.What I’ve Learned: Tips for Parents of Kids with ALL
My daughter Mackenzie was diagnosed with acute lymphoblastic leukemia (ALL) in January 2014. Despite being the most common form of childhood cancer that has a very prescribed protocol with better-than-most survival rates, the diagnosis petrified me. My nine-year-old had cancer.